undamentalytics Newsletter
Sign in

Absci Corp revenue

Absci Corp's revenue was $2.8m in fiscal 2025, down 38.2% on the year before. Since fiscal 2020 ($4.8m) it has grown at a compound -10.1% a year. Over the last twelve months it was $1.6m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue4,7804,7825,7475,7184,5342,8001,561
Growth on the year before—+0.0%+20.2%−0.5%−20.7%−38.2%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Absci Corp $1.6m -62.3% -43.3%
Ovid Therapeutics Inc. $1.6m -76.2% 99.8%
Cartesian Therapeutics, Inc. $1.5m 44.0% -68.8%
Dare Bioscience, Inc. $1.4m 4366.5% —
Seres Therapeutics, Inc. $1.9m 100.0% -75.6%
Korsana Biosciences, Inc. $1.9m -12.6% —

Compare with peers

Head to head: ABSI vs OVIDABSI vs RNACABSI vs DAREABSI vs MCRB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Absci Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Absci Corp.